Thrombophilia and adverse pregnancy outcome.
This article focuses on the clinical evaluation and management of women who have thrombophilia-related placental vascular complications, including fetal loss, pre-eclampsia, intrauterine fetal growth restriction, and placental abruption. All are major causes of maternal and fetal adverse outcomes.
Brenner
Benjamin
B
Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, PO Box 9602, Haifa 31096, Israel. b_brenner@rambam.health.gov.il
D000022:Abortion, Spontaneous / Q000209:etiology / Q000517:prevention & control; D000037:Abruptio Placentae / Q000453:epidemiology; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006487:Hemostasis; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009154:Mutation; D011225:Pre-Eclampsia / Q000209:etiology / Q000517:prevention & control; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D011256:Pregnancy Outcome; D019851:Thrombophilia / Q000150:complications* / Q000235:genetics / Q000517:prevention & control
D005343:Fibrinolytic Agents; D042965:Methylenetetrahydrofolate Reductase (NADPH2)